Navigation Links
Osteoporosis – A New Treatmen

Increasing the activity of a protein called NFATc1 tends to cause massive bone accumulation that target the drugs used to treat osteoporosis //- HHMI investigator Gerald Crabtree and HHMI predoctoral fellow Monte Winslow reports.

In vertebrates, bone is constantly being formed and being broken down throughout life. Cells called osteoclasts continuously degrade bone, while cells called osteoblasts replenish it.

‘Ideally, they are perfectly balanced,’ said Crabtree, the senior author of the study. ‘Over the course of a lifetime, if everything goes well, we'll maintain almost exactly identical bone mass.’ However, if the balance is upset, and more bone is destroyed than formed, osteoporosis results, increasing the risk of fractures.

The new study arose from the researchers' curiosity about reports that patients who were treated with the drug cyclosporine – often given to suppress the immune system before organ transplants – tended to lose bone mass. Those patients were also at increased risk of bone fractures, said first author Winslow, who led the study as an HHMI predoctoral fellow in Crabtree's lab. Winslow is now working as a postdoctoral fellow in the lab of HHMI investigator Tyler Jacks at the Massachusetts Institute of Technology.

Cyclosporine inhibits a signaling protein complex known as calcineurin, which chemically modifies the NFATc family of proteins. This modification changes its shape. With its new shape, NFATc can move into the nucleus of the cell, where it can trigger the activation of many genes. Although initially shown to regulate immune cell function, NFATc also functions in other cells to regulate heart development, blood vessel formation, neural development and function, and muscle development. Its function seems to depend on the time and place of its activation, like a context-sensitive key on a computer. In bone, it is NFATc1 that seems particularly important.

Since people with suppressed cal cineurin/NFATc activity experience bone loss, Winslow, Crabtree, and their colleagues wanted to see whether this pathway would be important in bone development and function as well. They studied mutant mice in which the NFATc1 in osteoblasts had been modified so that it could move more easily to the nucleus and become a little more active than usual.

Mice with the hyperactive NFATc in their osteoblasts had an immense increase in bone mass compared to normal mice, suggesting that the balance between bone formation and breakdown had tipped.

When the researchers examined the cells in these mice, they found that up-regulating NFATc signaling in osteoblasts increased the numbers of both types of bone cells. ‘It was clear that increased NFATc activity in osteoblasts influenced both osteoblasts and osteoclasts,’ Winslow said.

The researchers found that mice that showed enhanced NFATc activity in their osteoblasts had many more of these bone-forming cells, which explained the increase in bone mass. They also found a possible explanation for why there were more bone-destroying osteoclasts. Osteoblasts with hyperactive NFATc expressed higher levels of inflammatory proteins called chemokines, which promote osteoclast development.

‘Osteoblasts produce factors that recruit the progenitors of osteoclasts, and so when osteoblast numbers go up, osteoclast numbers go up,’ Crabtree said. This link between osteoblast and osteoclast numbers explains in part how the two types of cells normally stay balanced in animals, he added.

Mice with abnormally active NFATc probably develop so much bone mass because this delicate balance between osteoblasts and osteoclasts has been altered, Crabtree suggested. In the mutant mice, ‘there's also a huge increase in osteoclasts, but they never catch up,’ he said. ‘The balance has been tipped.’

This imbalance between bone formation and degradation could potentially be recreated by drug tre atments for osteoporosis, Crabtree said. Very little NFATc1 must be activated to build extra bone, Winslow noted, which means that it may be possible to up-regulate the calcineurin/NFATc pathway to promote bone formation without disturbing other organ systems that use this same pathway.

‘The results were dramatic, yet the molecular alteration is very, very minimal,’ Crabtree said. NFATc1 in the mice that developed extra bone mass was only 10 percent more active than it is in normal mice.

The researchers are now screening chemical libraries for small molecules that could increase NFATc just enough to promote bone formation in people with osteoporosis, without causing undesirable side effects. ‘If you could find a small molecule that would flip 10 percent of the existing NFATc into the active form,’ Crabtree said, ‘you could favor the formation of osteoblasts and make stronger bones.’

(Surce: Eurekalert)
'"/>




Related medicine news :

1. New treatment for Osteoporosis
2. Osteoporosis in men
3. Osteoporosis Drugs: right time to take-off
4. Fluoride Found Effective in Osteoporosis
5. Mutation connected to Osteoporosis
6. Osteoporosis associated with Childhood Cancer
7. A treatment for Osteoporosis
8. Osteoporosis could be caused by irregular periods
9. Back exercises reduces Osteoporosis
10. Osteoporosis and kidney stones gene marker identified
11. The Answer To Prevent Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... ... February 22, 2017 , ... ... the country today, as organizations, advocates, and individuals join together to increase recognition ... access to ultimately save lives. , “Today we mark a nationwide movement to ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, the ... featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” ... neurosurgeons in Michigan performing minimally invasive back surgery that often results in less ...
(Date:2/22/2017)... ... February 22, 2017 , ... Michael J. ... media platform connecting healthcare technology professionals and other key stakeholders with an array ... publication starting on March 1, announced Michael J. Hennessy, Jr., president of MJH ...
(Date:2/22/2017)... ... 2017 , ... Super-Sod will attend the Athens Home Show with a brand ... shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit space ... manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm in ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... who suffer from combat-related PTSD. , Established in 1977, our organization was at ... challenges of military returning to civilian life were evident and served as the ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Colo. , Feb. 22, 2017  Aytu BioScience, ... global commercialization of novel products in the field of ... team to up to 42 account managers from 35 ... The sales force expansion is being ... prescriptions and revenues, an indication of increasing acceptance of ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 According ... (Spectroscopy, Chromatography), Measurement (On-Line, In-Line, At-Line), Products and Services (Analyzers, Probes & ... to 2021", published by MarketsandMarkets, the global market is poised to reach ... a CAGR of 13.3% from 2016 to 2021. ... ...
(Date:2/22/2017)... Feb. 22, 2017  CVS Pharmacy is the first ... partially hydrogenated oils (PHO), the primary source of artificial ... store brands food products. The retailer now offers over ... from artificial trans fats. This comes a year and a ... of June 2018 for processed foods to be reformulated ...
Breaking Medicine Technology: